<SEC-DOCUMENT>0002057997-25-000002.txt : 20251121
<SEC-HEADER>0002057997-25-000002.hdr.sgml : 20251121
<ACCEPTANCE-DATETIME>20251121212611
ACCESSION NUMBER:		0002057997-25-000002
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240512
FILED AS OF DATE:		20251121
DATE AS OF CHANGE:		20251121

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Inscobee Inc.
		CENTRAL INDEX KEY:			0002057997
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42545
		FILM NUMBER:		251509433

	BUSINESS ADDRESS:	
		STREET 1:		ROOM 613, DIGITAL-RO 130, 6F
		STREET 2:		GEUMCHEON-GU
		CITY:			SEOUL
		STATE:			M5
		ZIP:			08580
		BUSINESS PHONE:		82-70-7600-7007

	MAIL ADDRESS:	
		STREET 1:		ROOM 613, DIGITAL-RO 130, 6F
		STREET 2:		GEUMCHEON-GU
		CITY:			SEOUL
		STATE:			M5
		ZIP:			08580

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apimeds Pharmaceuticals US, Inc.
		CENTRAL INDEX KEY:			0001894525
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851099700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		100 MATAWAN RD
		STREET 2:		SUITE 325
		CITY:			MATAWAN
		STATE:			NJ
		ZIP:			07747
		BUSINESS PHONE:		848-201-5010

	MAIL ADDRESS:	
		STREET 1:		100 MATAWAN RD
		STREET 2:		SUITE 325
		CITY:			MATAWAN
		STATE:			NJ
		ZIP:			07747
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2024-05-12</periodOfReport>

    <dateOfOriginalSubmission>2025-05-14</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001894525</issuerCik>
        <issuerName>Apimeds Pharmaceuticals US, Inc.</issuerName>
        <issuerTradingSymbol>APUS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002057997</rptOwnerCik>
            <rptOwnerName>Inscobee Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>ROOM 613, DIGITAL-RO 130, 6F</rptOwnerStreet1>
            <rptOwnerStreet2>GEUMCHEON-GU</rptOwnerStreet2>
            <rptOwnerCity>SEOUL</rptOwnerCity>
            <rptOwnerState>M5</rptOwnerState>
            <rptOwnerZipCode>08580</rptOwnerZipCode>
            <rptOwnerStateDescription>KOREA, REPUBLIC OF</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock, par value $0.0001 per share</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>4316618</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F1"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Apimeds Inc.</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The shares of common stock are owned directly by Apimeds Inc. (&quot;Apimeds Korea&quot;), which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.</footnote>
    </footnotes>

    <remarks>On May 14, 2025, the reporting person filed a Form 4 (the &quot;Form 4&quot;), which incorrectly reported that the reporting person had indirect beneficial ownership of a Convertible Promissory Note in the amount of $184,833 (the &quot;Note&quot;) and the shares of common stock underlying such Note (the &quot;Shares&quot;), through Apimeds Korea. On June 11, 2025, the reporting person filed an amendment to the Form 4 (the &quot;Original Amendment&quot;), to report that the reporting person directly owned the Note and the Shares. The Original Amendment did not update the holdings of Apimeds Korea to reflect that the Note and the Shares were directly owned by the reporting person. This amendment is being filed solely to correct Apimeds Korea's reported holdings. For the avoidance of doubt, as of May 12, 2025, the reporting person had direct beneficial ownership of 2,099,747 shares of common stock and indirect beneficial ownership of 4,316,618 shares of common stock held by Apimeds Korea.</remarks>

    <ownerSignature>
        <signatureName>/s/ Nelson Mullins Riley &amp; Scarborough LLP, Attorney-in-Fact</signatureName>
        <signatureDate>2025-11-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
